Isabelle Coornaert

Isabelle Coornaert

Auto-generated profile, based on publicly available information

Isabelle Coornaert

Laboratory of Physiopharmacology, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Universiteitsplein 1, 2610 Antwerp, Belgium

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Atherosclerosis
Verified
Journal Article
Closed access
ICIsabelle Coornaert
Isabelle Coornaert
PPPauline Puylaert
Pauline Puylaert
GMGiullia Marcasolli
Giullia Marcasolli
MGMandy O.J. Grootaert
Mandy O.J. Grootaert
PVPeter Vandenabeele
Peter Vandenabeele
WMWim Martinet
Wim Martinet

28 April 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
PPPauline Puylaert
Pauline Puylaert
ICIsabelle Coornaert
Isabelle Coornaert
CNCédric Neutel
Cédric Neutel
YDYves Dondelinger
Yves Dondelinger
TDTom Delanghe
Tom Delanghe
WMWim Martinet
Wim Martinet
RIPK1 (receptor-interacting serine/threonine-protein kinase 1) enzymatic activity drives both apoptosis and necroptosis, a regulated form of necrosis. Because necroptosis is involved in necrotic core development in atherosclerotic plaques, we investigated the effects of a RIPK1S25D/S25D mutation, which prevents activation of RIPK1 kinase, on atherogenesis in ApoE−/− mice. After 16 weeks of western-type diet (WD), atherosclerotic plaques from ApoE−/− RIPK1S25D/S25D mice were significantly larger compared to ApoE−/− RIPK1+/+ mice (167 ± 34 vs. 78 ± 18 × 103 µm2, p = 0.01). Cell numbers (350 ± 34 vs. 154 ± 33 nuclei) and deposition of glycosaminoglycans (Alcian blue: 31 ± 6 vs. 14 ± 4%, p = 0.023) were increased in plaques from ApoE−/− RIPK1S25D/S25D mice while macrophage content (Mac3: 2.3 ± 0.4 vs. 9.8 ± 2.4%, p = 0.012) was decreased. Plaque apoptosis was not different between both groups. In contrast, pharmacological inhibition of RIPK1 kinase with GSK’547 (10 mg/kg BW/day) in ApoE−/− Fbn1C1039G+/− mice, a model of advanced atherosclerosis, did not alter plaque size after 20 weeks WD, but induced apoptosis (TUNEL: 136 ± 20 vs. 62 ± 9 cells/mm2, p = 0.004). In conclusion, inhibition of RIPK1 kinase activity accelerated plaque progression in ApoE−/− RIPK1S25D/S25D mice and induced apoptosis in GSK’547-treated ApoE−/− Fbn1C1039G+/− mice. Thus, without directly comparing the genetic and pharmacological studies, it can be concluded that targeting RIPK1 kinase activity does not limit atherogenesis.

1 September 2021 in European Journal of Pharmacology
Verified
Journal Article
Closed access
SMSofie De Moudt
Sofie De Moudt
DMDorien De Munck
Dorien De Munck
ICIsabelle Coornaert
Isabelle Coornaert
PFPaul Fransen
Paul Fransen